Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02439957 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT02439957 is a Phase 3 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT02439957, a Phase 3 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy.
Interventions
- DRUG Valganciclovir
- DRUG Brincidofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02439957
The ClinicalTrials.gov registry entry for NCT02439957 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valganciclovir is the first listed.
NCT02439957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02439957 about?
NCT02439957 is a clinical study titled "A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus". This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymph...
What is the current status of trial NCT02439957?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2015-09. Estimated completion is 2016-07-31.
What interventions are being tested in trial NCT02439957?
The interventions under investigation include: Valganciclovir (DRUG), Brincidofovir (DRUG).
Who is sponsoring clinical trial NCT02439957?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.